Bloomberg Intelligence cover image

Hunter Biden, Eli Lilly, CAVA, and Geopolitics (Podcast)

Bloomberg Intelligence

00:00

Eli Lilly's Moongiaro Drug

Eli Lilly is spending $10 billion a year on R&D, but the company says it doesn't need any debt to fund its new drug development. Samidhar: It makes me kind of chuck a little bit when interest rates are shooting up where you would think that M-A would be less likely. "Nobody really cares as long as internal R&D ... delivering something," he said.

Play episode from 12:50
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app